Gamifant (emapalumab-lzsg) Coverage Policy
Customize your policy alerts
Sign up for Molina Healthcare Policy C15970-A alerts
Get alerted when Policy C15970-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs Molina Healthcare coverage and prior authorization for Gamifant (emapalumab-lzsg) used to treat primary or secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Coverage is subject to member benefit eligibility, clinical criteria, required documentation, prescriber qualifications, and authorization duration limits.
The revision history identifies notable revisions to the Diagnosis and Quantity sections in Q3 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.